StonvexLoading…
StonvexStonvexStonvexCore line items from MRNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-30 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $103.82M | $389.00M | $1.94B | $1.27B | $250.00M |
Operating Income | Not available | $-1.39B | $-3.07B | $-2.22B | $-1.96B |
Net Income | Not available | $-1.34B | $-2.82B | $-2.00B | $-1.80B |
EPS (Diluted) | $-2.13 | $-3.40 | $-7.26 | $-5.15 | $-4.64 |
Total Assets | Not available | $11.49B | $12.34B | $12.13B | $12.01B |
Total Liabilities | Not available | $4.08B | $3.69B | $2.81B | $2.61B |
Cash & Equivalents | Not available | $1.91B | $2.60B | $1.13B | $1.28B |
Free Cash Flow OCF − CapEx | Not available | $-692.00M | $-2.06B | $-2.96B | $-2.08B |
Shares Outstanding | Not available | 397.00M | 394.00M | 391.00M | 389.00M |